267 related articles for article (PubMed ID: 24277700)
1. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.
Aprile G; Bonotto M; Ongaro E; Pozzo C; Giuliani F
Drugs; 2013 Dec; 73(18):2003-15. PubMed ID: 24277700
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab (IMC-1121B): a novel attack on angiogenesis.
Spratlin JL; Mulder KE; Mackey JR
Future Oncol; 2010 Jul; 6(7):1085-94. PubMed ID: 20624120
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
Clarke JM; Hurwitz HI
Expert Opin Biol Ther; 2013 Aug; 13(8):1187-96. PubMed ID: 23803182
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic agent ramucirumab: meaningful or marginal?
Wadhwa R; Elimova E; Shiozaki H; Sudo K; Blum MA; Estrella JS; Chen Q; Song S; Ajani JA
Expert Rev Anticancer Ther; 2014 Apr; 14(4):367-79. PubMed ID: 24605771
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.
Spratlin J
Curr Oncol Rep; 2011 Apr; 13(2):97-102. PubMed ID: 21222245
[TBL] [Abstract][Full Text] [Related]
7. Clinical advances in the development of novel VEGFR2 inhibitors.
Fontanella C; Ongaro E; Bolzonello S; Guardascione M; Fasola G; Aprile G
Ann Transl Med; 2014 Dec; 2(12):123. PubMed ID: 25568876
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab: a novel antiangiogenic agent.
Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
Javle M; Smyth EC; Chau I
Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with ramucirumab : outcomes in breast cancer.
O'Sullivan Coyne G; Burotto M
Expert Opin Biol Ther; 2014 Sep; 14(9):1351-60. PubMed ID: 25018016
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
15. The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.
Calvetti L; Pilotto S; Carbognin L; Ferrara R; Caccese M; Tortora G; Bria E
Expert Opin Biol Ther; 2015; 15(9):1359-70. PubMed ID: 26190526
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
Krupitskaya Y; Wakelee HA
Curr Opin Investig Drugs; 2009 Jun; 10(6):597-605. PubMed ID: 19513949
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab: preclinical research and clinical development.
Aprile G; Rijavec E; Fontanella C; Rihawi K; Grossi F
Onco Targets Ther; 2014; 7():1997-2006. PubMed ID: 25378934
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.
Gambardella V; Tarazona N; Cejalvo JM; Roselló S; Cervantes A
Expert Opin Drug Metab Toxicol; 2016; 12(4):449-56. PubMed ID: 26895445
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
